Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

54.00 +0.45 (+0.84%)
Streaming Delayed Price Updated: 9:56 AM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade ↗
Now could be a great time to scoop up three stocks trading way below their previous peaks. 
Via The Motley Fool
News headline image
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100 ↗
These dividend payers could more than double their payouts in the decade ahead. 
Via The Motley Fool
News headline image
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut ↗
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company... 
Via Benzinga
News headline image
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation' ↗
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round." 
Via Benzinga
News headline image
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024 ↗
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Royalty Pharma Reports Second Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Third Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? ↗
CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing. 
Via Investor's Business Daily
News headline image
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 ↗
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge. 
Via InvestorPlace
News headline image
7 Biotech Stocks to Buy on the Dip: June 2024 ↗
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
News headline image
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? ↗
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval. 
Via Benzinga
News headline image
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out ↗
The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug. 
Via Investor's Business Daily
News headline image
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe ↗
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion. 
Via Benzinga
News headline image
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
From Royalty Pharma plc; Cytokinetics
Via GlobeNewswire
News headline image
7 Dividend Stocks to Buy at a 52-Week Low ↗
For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low. 
Via InvestorPlace
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024 ↗
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Royalty Pharma Reports First Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment ↗
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.